Institutional shares held 14.5 Million
538K calls
26.3K puts
Total value of holdings $30.3M
$1.12M calls
$54K puts
Market Cap $43M
20,551,900 Shares Out.
Institutional ownership 70.5%
# of Institutions 52


Latest Institutional Activity in SLS

Top Purchases

Q2 2025
Marshall Financial Group LLC Shares Held: 10.3K ($21.5K)
Q2 2025
Brooklyn Fi, LLC Shares Held: 10.2K ($21.4K)
Q1 2025
Anson Funds Management LP Shares Held: 7.58M ($15.8M)
Q1 2025
Susquehanna International Group, LLP Shares Held: 689K ($1.44M)
Q1 2025
Vanguard Group Inc Shares Held: 2.84M ($5.93M)

Top Sells

Q1 2025
Citadel Advisors LLC Shares Held: 350K ($730K)
Q1 2025
Ubs Group Ag Shares Held: 62.2K ($130K)
Q1 2025
Sbi Securities Co., Ltd. Shares Held: 5.43K ($11.3K)
Q4 2024
Xtx Topco LTD Shares Held: 53.4K ($112K)
Q4 2024
Advisor Group Holdings, Inc. Shares Held: 1.66K ($3.47K)

About SLS

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.


Insider Transactions at SLS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1M Shares
From 11 Insiders
Grant, award, or other acquisition 952K shares
Open market or private purchase 50K shares
Sell / Disposition
43.7K Shares
From 3 Insiders
Other acquisition or disposition 43.7K shares

Track Institutional and Insider Activities on SLS

Follow SELLAS Life Sciences Group, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SLS shares.

Notify only if

Insider Trading

Get notified when an Sellas Life Sciences Group, Inc. insider buys or sells SLS shares.

Notify only if

News

Receive news related to SELLAS Life Sciences Group, Inc.

Track Activities on SLS